While I essentially agree with you, it has been a badly battered stock for the last 5 years since the takeover of ARQ. IMHO I hope your prediction is right
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
